Glucocorticoid/NN
receptors/NNS
in/IN
systemic/JJ
lupus/NN
erythematosus/NN
./.

Glucocorticosteroids/NNS
remain/VBP
the/DT
major/JJ
treatment/NN
modality/NN
for/IN
systemic/JJ
lupus/NN
erythematosus/NN
(/(
SLE/NN
)/)
,/,
but/CC
their/PRP$
mechanism/NN
of/IN
action/NN
is/VBZ
unclear/JJ
./.
=====
Over/IN
the/DT
past/JJ
decade/NN
it/PRP
has/VBZ
become/VBN
clear/JJ
that/IN
glucocorticosteroid/NN
receptors/NNS
play/VBP
a/DT
significant/JJ
role/NN
in/IN
the/DT
mechanism/NN
of/IN
glucocorticosteroid/NN
action/NN
./.
=====
We/PRP
studied/VBD
glucocorticosteroid/NN
receptor/NN
density/NN
and/CC
affinity/NN
on/IN
peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
by/IN
the/DT
glucocorticosteroid/NN
binding/NN
assay/NN
in/IN
33/CD
patients/NNS
with/IN
SLE/NN
who/WP
had/VBD
taken/VBN
no/DT
glucocorticosteroid/NN
for/IN
the/DT
previous/JJ
6/CD
months/NNS
and/CC
in/IN
32/CD
healthy/JJ
controls/NNS
./.
=====
Patients/NNS
'/POS
disease/NN
activity/NN
was/VBD
measured/VBN
by/IN
the/DT
SLE/NN
Disease/NN
Activity/NN
Index/NN
(/(
SLEDAI/NN
)/)
./.
=====
Glucocorticosteroid/NN
receptors/NNS
on/IN
leukocytes/NNS
of/IN
patients/NNS
with/IN
SLE/NN
were/VBD
significantly/RB
higher/JJR
than/IN
in/IN
healthy/JJ
controls/NNS
(/(
4419/CD
+/-/CC
306/CD
vs/CC
3369/CD
+/-/CC
196/CD
,/,
p/NN
less/JJR
than/IN
0.005/CD
)/)
./.
=====
The/DT
binding/NN
affinity/NN
was/VBD
not/RB
different/JJ
between/IN
patients/NNS
and/CC
controls/NNS
./.
=====
There/EX
was/VBD
no/DT
correlation/NN
between/IN
glucocorticosteroid/NN
receptor/NN
number/NN
and/CC
SLE/NN
disease/NN
activity/NN
./.